Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gemcitabine hydrochloride

View Patient Information
The hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:difluorodeoxycytidine hydrochloride
gemcitabine HCI
US brand name:Gemzar
Infugem
Abbreviation:dFdCyd
Code name:LY-188011
LY188011
Chemical structure:1-(2-oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose hydrochloride
1-(2-oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, hydrochloride
2'-deoxy-2',2'-difluorocytidine hydrochloride
2'deoxy-2',2'-difluorocytidine hydrochloride
2'deoxy-2',2'-difluorocytidine, hydrochloride
NSC code:613327
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search